Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Modeling hematopoietic disorders in zebrafish.

Konantz M, Schürch C, Hanns P, Müller JS, Sauteur L, Lengerke C.

Dis Model Mech. 2019 Sep 6;12(9). pii: dmm040360. doi: 10.1242/dmm.040360. Review.

2.

SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond.

Schaefer T, Lengerke C.

Oncogene. 2019 Sep 2. doi: 10.1038/s41388-019-0997-x. [Epub ahead of print] Review.

PMID:
31477842
3.

Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.

Fischer AK, Pham DL, Bösmüller H, Lengerke C, Wagner P, Bachmann C, Beschorner C, Perner S, Kommoss S, Fend F, Staebler A.

Virchows Arch. 2019 Oct;475(4):479-488. doi: 10.1007/s00428-019-02647-0. Epub 2019 Aug 27.

PMID:
31451895
4.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7770):E19. doi: 10.1038/s41586-019-1475-x.

PMID:
31367045
5.

Stress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis.

Hanns P, Paczulla AM, Medinger M, Konantz M, Lengerke C.

Cell Stress. 2019 Jun 4;3(7):221-235. doi: 10.15698/cst2019.07.192. Review.

6.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Erratum in: Nature. 2019 Aug 1;:.

PMID:
31316209
7.

Zebrafish Xenografts for the In Vivo Analysis of Healthy and Malignant Human Hematopoietic Cells.

Konantz M, Müller JS, Lengerke C.

Methods Mol Biol. 2019;2017:205-217. doi: 10.1007/978-1-4939-9574-5_16.

PMID:
31197779
8.

Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment.

Medinger M, Drexler B, Lengerke C, Passweg J.

Front Oncol. 2018 Dec 5;8:587. doi: 10.3389/fonc.2018.00587. eCollection 2018. Review.

9.

Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Bianchi M, Heim D, Lengerke C, Halter J, Gerull S, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M.

Ann Hematol. 2019 Apr;98(4):971-977. doi: 10.1007/s00277-018-3577-1. Epub 2018 Dec 12.

PMID:
30542943
10.

Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.

Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, Schürch C, Müller J, Schärer J, Moffa G, Demougin P, Moes S, Stippich C, Falbo S, Neddersen H, Bucher H, Frank S, Jenö P, Lengerke C, Ritz MF, Mariani L, Boulay JL.

Brain Pathol. 2019 May;29(3):336-350. doi: 10.1111/bpa.12670. Epub 2018 Dec 21.

PMID:
30403311
11.

Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer.

Porta F, Ehrsam D, Lengerke C, Meyer Zu Schwabedissen HE.

Mol Pharm. 2018 Nov 5;15(11):4884-4897. doi: 10.1021/acs.molpharmaceut.8b00521. Epub 2018 Oct 15.

PMID:
30274515
12.

High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.

Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M.

Bone Marrow Transplant. 2019 Apr;54(4):540-548. doi: 10.1038/s41409-018-0293-3. Epub 2018 Aug 14.

PMID:
30108323
13.

In vitro biomimetic engineering of a human hematopoietic niche with functional properties.

Bourgine PE, Klein T, Paczulla AM, Shimizu T, Kunz L, Kokkaliaris KD, Coutu DL, Lengerke C, Skoda R, Schroeder T, Martin I.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5688-E5695. doi: 10.1073/pnas.1805440115. Epub 2018 Jun 4.

14.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
15.

Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids.

Jacob F, Alam S, Konantz M, Liang CY, Kohler RS, Everest-Dass AV, Huang YL, Rimmer N, Fedier A, Schötzau A, Lopez MN, Packer NH, Lengerke C, Heinzelmann-Schwarz V.

Cancer Res. 2018 Jun 1;78(11):2952-2965. doi: 10.1158/0008-5472.CAN-17-2223. Epub 2018 Mar 23.

16.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

17.

In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.

Krupar R, Schreiber C, Offermann A, Lengerke C, Sikora AG, Thorns C, Perner S.

Leuk Lymphoma. 2018 Oct;59(10):2493-2496. doi: 10.1080/10428194.2018.1434883. Epub 2018 Feb 12. No abstract available.

PMID:
29431550
18.

In Vitro Tumorigenic Assay: The Tumor Spheres Assay.

Wang H, Paczulla AM, Konantz M, Lengerke C.

Methods Mol Biol. 2018;1692:77-87. doi: 10.1007/978-1-4939-7401-6_7.

PMID:
28986888
19.

Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features.

Carapito R, Konantz M, Paillard C, Miao Z, Pichot A, Leduc MS, Yang Y, Bergstrom KL, Mahoney DH, Shardy DL, Alsaleh G, Naegely L, Kolmer A, Paul N, Hanauer A, Rolli V, Müller JS, Alghisi E, Sauteur L, Macquin C, Morlon A, Sancho CS, Amati-Bonneau P, Procaccio V, Mosca-Boidron AL, Marle N, Osmani N, Lefebvre O, Goetz JG, Unal S, Akarsu NA, Radosavljevic M, Chenard MP, Rialland F, Grain A, Béné MC, Eveillard M, Vincent M, Guy J, Faivre L, Thauvin-Robinet C, Thevenon J, Myers K, Fleming MD, Shimamura A, Bottollier-Lemallaz E, Westhof E, Lengerke C, Isidor B, Bahram S.

J Clin Invest. 2017 Nov 1;127(11):4090-4103. doi: 10.1172/JCI92876. Epub 2017 Oct 3.

20.

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.

21.

Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice.

Paczulla AM, Dirnhofer S, Konantz M, Medinger M, Salih HR, Rothfelder K, Tsakiris DA, Passweg JR, Lundberg P, Lengerke C.

Haematologica. 2017 May;102(5):854-864. doi: 10.3324/haematol.2016.153528. Epub 2017 Feb 9.

22.

Evi1 regulates Notch activation to induce zebrafish hematopoietic stem cell emergence.

Konantz M, Alghisi E, Müller JS, Lenard A, Esain V, Carroll KJ, Kanz L, North TE, Lengerke C.

EMBO J. 2016 Nov 2;35(21):2315-2331. Epub 2016 Sep 16.

23.

Novel therapeutic options in Acute Myeloid Leukemia.

Medinger M, Lengerke C, Passweg J.

Leuk Res Rep. 2016 Oct 1;6:39-49. eCollection 2016. Review.

24.

Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, Deng M, Vogel W, von Mässenhausen A, Kristiansen G, Duensing S, Kirfel J, Lengerke C, Perner S.

Oncogene. 2017 Mar;36(11):1573-1584. doi: 10.1038/onc.2016.325. Epub 2016 Sep 12.

PMID:
27617580
25.

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.

Medinger M, Lengerke C, Passweg J.

Cancer Genomics Proteomics. 2016 09-10;13(5):317-29. Review.

26.

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, Duyster J, Kanz L, Passweg J, Finke J, Bethge W, Lengerke C.

Ann Hematol. 2016 Oct;95(10):1627-36. doi: 10.1007/s00277-016-2758-z. Epub 2016 Aug 2.

PMID:
27480090
27.

Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.

von Mässenhausen A, Sanders C, Brägelmann J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F, Brossart P, Kirfel J, Lengerke C, Perner S.

Int J Cancer. 2016 Nov 15;139(10):2359-69. doi: 10.1002/ijc.30279. Epub 2016 Jul 30.

28.

Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents.

Medinger M, Halter J, Heim D, Buser A, Gerull S, Lengerke C, Passweg J.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):275-9.

PMID:
27365377
29.

Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.

Medinger M, Heim D, Gerull S, Halter J, Krenger W, Buser A, Lengerke C, Bucher C, Passweg J.

Leuk Res. 2016 Aug;47:22-5. doi: 10.1016/j.leukres.2016.05.011. Epub 2016 May 17.

PMID:
27239737
30.

Endothelial-to-hematopoietic transition: Notch-ing vessels into blood.

Kanz D, Konantz M, Alghisi E, North TE, Lengerke C.

Ann N Y Acad Sci. 2016 Apr;1370(1):97-108. doi: 10.1111/nyas.13030. Epub 2016 Mar 25.

PMID:
27015586
31.

Using zebrafish to model erythroid lineage toxicity and regeneration.

Lenard A, Alghisi E, Daff H, Donzelli M, McGinnis C, Lengerke C.

Haematologica. 2016 May;101(5):e164-7. doi: 10.3324/haematol.2016.142562. Epub 2016 Mar 4. No abstract available.

32.

AKT-driven phospho-patterns of pluripotency.

Schaefer T, Lengerke C.

Cell Cycle. 2015;14(24):3784-5. doi: 10.1080/15384101.2015.1115642. No abstract available.

33.

Molecular and functional interactions between AKT and SOX2 in breast carcinoma.

Schaefer T, Wang H, Mir P, Konantz M, Pereboom TC, Paczulla AM, Merz B, Fehm T, Perner S, Rothfuss OC, Kanz L, Schulze-Osthoff K, Lengerke C.

Oncotarget. 2015 Dec 22;6(41):43540-56. doi: 10.18632/oncotarget.6183.

34.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

35.

Innate immune system favors emergency monopoiesis at the expense of DC-differentiation to control systemic bacterial infection in mice.

Pasquevich KA, Bieber K, Günter M, Grauer M, Pötz O, Schleicher U, Biedermann T, Beer-Hammer S, Bühring HJ, Rammensee HG, Zender L, Autenrieth IB, Lengerke C, Autenrieth SE.

Eur J Immunol. 2015 Oct;45(10):2821-33. doi: 10.1002/eji.201545530. Epub 2015 Jul 24.

36.

Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation.

Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A, Lengerke C, Weisser M, Passweg JR.

Bone Marrow Transplant. 2015 Oct;50(10):1331-6. doi: 10.1038/bmt.2015.148. Epub 2015 Jun 29.

PMID:
26121111
37.

The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M.

Leukemia. 2015 Oct;29(10):2003-14. doi: 10.1038/leu.2015.114. Epub 2015 May 4.

PMID:
25936528
38.

Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.

Shaikhibrahim Z, Offermann A, Halbach R, Vogel W, Braun M, Kristiansen G, Bootz F, Wenzel J, Mikut R, Lengerke C, Reischl M, Schröck A, Perner S.

Am J Pathol. 2015 Apr;185(4):1114-22. doi: 10.1016/j.ajpath.2014.12.010. Epub 2015 Mar 16.

PMID:
25791637
39.

Evaluation of stem cell properties in human ovarian carcinoma cells using multi and single cell-based spheres assays.

Wang H, Paczulla A, Lengerke C.

J Vis Exp. 2015 Jan 3;(95):e52259. doi: 10.3791/52259.

40.

When the going gets tough: scientists' personal challenges.

Lengerke C, Fernandez-Capetillo O, Tolic-Norrelykke I, Barna M, Coleman T, Zamboni D.

Cell. 2014 Oct 9;159(2):225-6. No abstract available.

41.

Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma.

Schröck A, Bode M, Göke FJ, Bareiss PM, Schairer R, Wang H, Weichert W, Franzen A, Kirsten R, van Bremen T, Queisser A, Kristiansen G, Heasley L, Bootz F, Lengerke C, Perner S.

Carcinogenesis. 2014 Jul;35(7):1636-42. doi: 10.1093/carcin/bgu094. Epub 2014 Apr 17.

PMID:
24743512
42.

Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer.

Schröck A, Göke F, Wagner P, Bode M, Franzen A, Huss S, Agaimy A, Ihrler S, Kirsten R, Kristiansen G, Bootz F, Lengerke C, Perner S.

Head Neck. 2014 Sep;36(9):1253-7. doi: 10.1002/hed.23443. Epub 2014 Feb 1.

PMID:
23913758
43.

SOX2 expression associates with stem cell state in human ovarian carcinoma.

Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler A, Wallwiener D, Fend F, Fehm T, Pichler B, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K, Essmann F, Lengerke C.

Cancer Res. 2013 Sep 1;73(17):5544-55. doi: 10.1158/0008-5472.CAN-12-4177. Epub 2013 Jul 18.

44.

SOX2 expression and prognostic significance in ovarian carcinoma.

Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, Adam A, Bachmann C, Neubauer H, Boesmueller H, Kanz L, Wallwiener D, Fend F, Lengerke C, Perner S, Fehm T, Staebler A.

Int J Gynecol Pathol. 2013 Jul;32(4):358-67. doi: 10.1097/PGP.0b013e31826a642b.

PMID:
23722508
45.

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.

Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schröck A, Perner S.

Mod Pathol. 2013 Oct;26(10):1298-306. doi: 10.1038/modpathol.2013.58. Epub 2013 Apr 26.

46.

Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer.

Schröck A, Göke F, Wagner P, Bode M, Franzen A, Braun M, Huss S, Agaimy A, Ihrler S, Menon R, Kirsten R, Kristiansen G, Bootz F, Lengerke C, Perner S.

PLoS One. 2013;8(3):e59201. doi: 10.1371/journal.pone.0059201. Epub 2013 Mar 27.

47.

Prospective isolation of mesenchymal stem cells from human bone marrow using novel antibodies directed against Sushi domain containing 2.

Sivasubramaniyan K, Harichandan A, Schumann S, Sobiesiak M, Lengerke C, Maurer A, Kalbacher H, Bühring HJ.

Stem Cells Dev. 2013 Jul 1;22(13):1944-54. doi: 10.1089/scd.2012.0584. Epub 2013 Mar 18.

PMID:
23406305
48.

Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development.

Jain MV, Paczulla AM, Klonisch T, Dimgba FN, Rao SB, Roberg K, Schweizer F, Lengerke C, Davoodpour P, Palicharla VR, Maddika S, Łos M.

J Cell Mol Med. 2013 Jan;17(1):12-29. doi: 10.1111/jcmm.12001. Epub 2013 Jan 10. Review.

49.

The transcriptional landscape of hematopoietic stem cell ontogeny.

McKinney-Freeman S, Cahan P, Li H, Lacadie SA, Huang HT, Curran M, Loewer S, Naveiras O, Kathrein KL, Konantz M, Langdon EM, Lengerke C, Zon LI, Collins JJ, Daley GQ.

Cell Stem Cell. 2012 Nov 2;11(5):701-14. doi: 10.1016/j.stem.2012.07.018.

50.

Zebrafish xenografts as a tool for in vivo studies on human cancer.

Konantz M, Balci TB, Hartwig UF, Dellaire G, André MC, Berman JN, Lengerke C.

Ann N Y Acad Sci. 2012 Aug;1266:124-37. doi: 10.1111/j.1749-6632.2012.06575.x. Review.

PMID:
22901264

Supplemental Content

Loading ...
Support Center